HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options    My Account    Help    

Zacks Video
The greatest minds behind Zacks.com step in front of the camera to analyze the market and promising stocks. Click here to tune in.
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Equity Research
My Portfolio
Stock Screener
Profit Tracks
Mutual Funds
Options
Zacks Video
RSS Feed
Profit from the Pros

Subscription Services
Product Guide
Zacks Premium
Zacks Elite
Method for Trading
Chart Patterns Trader
Double Your Money
ETF Trader
Growth Trader
Options Trader
Strategic Investor
Surprise Trader
Top 10 Stocks
Value Trader
Special Reports
Research Wizard

Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive


NCST: Nucryst Pharmaceuticals Corp - Stock Quote Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Quote |  Detailed Quotes |  Real Time |  Options Chain |  Greeks Montage

NUCRYST PHARMACEUTICALS CORP (NASD)
NCST 1.00 -0.03 (-2.91%) Vol.  6,160 15:59 ET

Day Low - High 0.99 - 1.03
52wk Low - High 0.25 - 1.30
Avg Volume 18,913
Industry MED-DRUGS
Market Cap 18.33 M
Div - Yield 0.80 - 80.00
PE (forward)
PEG Ratio N/A
Current Year Est. N/A
EPS Last Year -0.12
Detailed Quote


Premium Research: Stock Analysis

Zacks Rank

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.
Zacks Rank Definition Annualized Return
#1 Strong Buy 26.51%
#2 Buy 16.63%
#3 Hold 7.53%
#4 Sell 2.01%
#5 Strong Sell -0.07%
S&P 500 8.70%
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank


Short-Term Rating 1-3 Months
PREMIUM
Zacks Recommendation

Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.

The Zacks Recommendations are split into 3 groups: Outperform, Neutral and Underperform. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock. More on these reports below.

Difference Between Zacks Rank and Zacks Recommendation
Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations


Long-Term Rating 6+ Months
PREMIUM
Zacks Industry Rank

Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.

When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

About Zacks Industry Rank
Zacks Industry Rank - All current industry ranks.
Zacks Premium - The only way to get access to the Zacks Industry Rank

PREMIUM
Target Price

The Zacks Price Target provides you our expectation for a stocks share price in the next 6 months. These price targets are created by the Zacks Equity Research group to coincide with their recommendations that are also based on a 6 month time horizon.

Zacks Equity Research Home
Zacks Premium - The only way to get access to the Zacks Price Targets

PREMIUM
Equity Research Report

The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

Zacks Equity Research Home Zacks Premium - The only way to get access to Zacks Recommendations


Updated as of 03/02/2009
PREMIUM
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium

Premium Research: Industry Analysis

Top Peers Ticker Zacks Rank
NUCRYST PHARMACEUTICALS CORP NCST PREMIUM
ASTRAZENECA PLC AZN PREMIUM
SUPERGEN INC SUPG PREMIUM
VALEANT PHARMA VRX PREMIUM
See all MED-DRUGS Peers

BROKERAGE RECOMMENDATIONS
Current ABR N/A
ABR (Last Week) N/A
# of Recs in ABR N/A
Average Target Price N/A
Industry Rank by ABR 44 out of 217
Rank in Industry 188 out of 114
More Brokerage Recommendations

Zacks Community PeopleAndPicks.com
Community Rating

PeopleAndPicks.com Community Stock Ratings

Rating Recommendation % of Stocks
5 stars Strong Buy 10%
4 stars Buy 20%
3 stars Hold 40%
2 stars Sell 20%
1 stars Strong Sell 10%
0 stars Not Rated  

We believe that a community of investors working together can create a superior stock rating system. Some call this "collective intelligence". Or simply...together we can beat the market!

A stock's Community Rating is calculated based on the aggregate input of the PeopleAndPicks Community. The proportion of buy to sell ratings, recency of analysis, and the average score of the users who rate it favorably all factor into a score of one to five stars.


How do you rate NCST?
Buy
Sell
Find out what the Zacks Community
thinks of NCST at PeopleAndPicks.com

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

 Interactive Java Charting
 Comparative Chart



 
ZACKS COMMENTARY FOR NCST
Zacks Equity Research: Report for NCST
Mar 02, 2009
:
More Zacks Commentary
NEWS
NUCRYST Receives Deficiency Notice from NASDAQ
Sep 18, 2009
European Launch of Acticoat(TM) Flex with NUCRYST's Nanocrystalline Silver Technology Announced by Smith Nephew
Sep 03, 2009
NCST: Q2 Earnings Call @ 09:00 ET Today [delayed]
Aug 05, 2009
NUCRYST announces 2009 second quarter financial results
Aug 05, 2009
Conference Calls Today: 8-9:30 A.M. EDT
Aug 05, 2009
More News
EARNINGS ESTIMATES
  This Quarter
N/A
Next Quarter
N/A
This Year
N/A
Next Year
N/A
Average Estimate N/A N/A N/A N/A
Number of Estimates N/A N/A N/A N/A
Low Estimates N/A N/A N/A N/A
High Estimate N/A N/A N/A N/A
Year Ago EPS N/A N/A N/A N/A
EPS Growth N/A% N/A% N/A% N/A%

More Estimates

COMPANY DESCRIPTION
Nucryst Pharmaceuticals develops, manufactures and commercializes medical products that fight infection and inflammation based on its nanocrystalline silver technology. Advanced wound care products with the company's Silcryst coatings are sold by Smith & Nephew plc under an exclusive license under its Acticoat trademark. Nucryst is also developing pharmaceutical products to address medical conditions that are characterized by both infection and inflammation. The company has developed its nanocrystalline silver in a powder form for use as an active pharmaceutical ingredient.

Full Company Report
FINANCIALS
EPS TTM -.12
Sales 20.91
Net Income -.57
Price/Earnings N/A
Price/Book .79
Price/Cash Flow N/A
Price/Sales .91


More Financials

 
About Zacks | Advertise | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2009 Zacks Investment Research